Search research articles
Contact Us
Filters
Showing results (171-180 of 227) with videos related to
Page
of 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2004
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
David F McDermott, Meredith M Regan, Joseph I Clark, et al.
European Urology
|
November 5, 2013
The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium
Fabio A B Schutz, Wanling Xie, Frede Donskov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2007
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference
Michael B Atkins, Marc S Ernstoff, Robert A Figlin, et al.
Molecular Cancer Therapeutics
|
October 17, 2014
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma
David J Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, et al.
Nature Communications
|
September 27, 2019
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
Haoxin Li, Kevin Bullock, Carino Gurjao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2019
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
Jean-Christophe Pignon, Opeyemi Jegede, Sachet A Shukla, et al.
European Urology
|
March 8, 2021
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial
Thomas Powles, Michael B Atkins, Bernard Escudier, et al.
The Lancet. Oncology
|
September 14, 2016
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F Stephen Hodi, Jason Chesney, Anna C Pavlick, et al.
Cancer
|
January 19, 2010
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
Walter M Stadler, Robert A Figlin, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Meredith M Regan, Opeyemi A Jegede, Charlene M Mantia, et al.
Page
of 23
Search research articles
Search
Showing results (171-180 of 227) with videos related to
Sort By:
Page
of 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2004
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
David F McDermott, Meredith M Regan, Joseph I Clark, et al.
European Urology
|
November 5, 2013
The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium
Fabio A B Schutz, Wanling Xie, Frede Donskov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2007
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference
Michael B Atkins, Marc S Ernstoff, Robert A Figlin, et al.
Molecular Cancer Therapeutics
|
October 17, 2014
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma
David J Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, et al.
Nature Communications
|
September 27, 2019
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
Haoxin Li, Kevin Bullock, Carino Gurjao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2019
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
Jean-Christophe Pignon, Opeyemi Jegede, Sachet A Shukla, et al.
European Urology
|
March 8, 2021
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial
Thomas Powles, Michael B Atkins, Bernard Escudier, et al.
The Lancet. Oncology
|
September 14, 2016
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F Stephen Hodi, Jason Chesney, Anna C Pavlick, et al.
Cancer
|
January 19, 2010
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
Walter M Stadler, Robert A Figlin, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Meredith M Regan, Opeyemi A Jegede, Charlene M Mantia, et al.
Page
of 23